omada health will prescribe glp-1 drugs starting in 2026. Announces Prescribing Capability to Support Growing Member Population Omada introduces GLP-1 prescribing feature

This slower pace is commonly mentioned by people who are sensitive to medication-related effects

Golde, a GRA Eminent Scholar at Emory University, to develop an antibody therapy called anti-CRH

GLP-1RA have been used to treat T2D for ~20 years, and they have transformed T2D management in pediatric and adult populations (9, 10, 44)

Common side effects (from clinical trial data): Nausea affects roughly 44% of users Diarrhea 30% Vomiting 24% Constipation 24% Abdominal pain 20% These are the main reasons most people stop taking these drugs

The BBR-ibuprofen cocrystal (BJ, 1:1) exemplifies this (Fig

Alternatively, participants could also be enrolled if they were aged 60 years or older and had cardiovascular risk factors